Pharmaceutical Market Research Company in Poland

For pharmaceutical and life-sciences decisions in the Polish market, BioNixus is a leading specialist: AOTMiT-aligned study design, Ministry of Health reimbursement and NFZ payer context, HCP and KOL recruitment across major Polish academic medical centres, and outputs built for launch, market access, and lifecycle management teams.

Pharmaceutical market research in Poland is evidence generation for drug launch, market access, and lifecycle decisions across URPL, EMA centralised approval, AOTMiT HTA, Ministry of Health reimbursement, and NFZ payer contexts. BioNixus focuses on physician behavior, payer and reimbursement dynamics, and institution-level adoption so commercial and access teams can prioritize Polish market execution across oncology, immunology, cardiovascular, and rare disease therapy areas.

Poland's Reimbursement Act of 2011 established the framework for official pricing and public reimbursement of medicines, including formal price negotiation with the Ministry of Health, the use of risk-sharing schemes (instrumenty dzielenia ryzyka / RSS), and AOTMiT cost-effectiveness assessment referencing a threshold of approximately three times GDP per capita per QALY. This has significantly shaped commercial strategy for new product launches, particularly in oncology and rare disease. BioNixus conducts reimbursement impact research: payer and Ministry of Health strategy studies, HCP pricing perception research, and commercial team intelligence on how reimbursement listing decisions and risk-sharing schemes affect market access dynamics.

BioNixus covers all major Polish payer and access segments: NFZ (Narodowy Fundusz Zdrowia / National Health Fund) as the single public payer, AOTMiT health technology assessment and tariff recommendations, Ministry of Health reimbursement listing (obwieszczenie refundacyjne) and price negotiation under the Reimbursement Act, and risk-sharing schemes (instrumenty dzielenia ryzyka / RSS). Research includes in-depth interviews with reimbursement decision makers and hospital pharmacy leads, reimbursement listing studies, drug programme (programy lekowe) access intelligence, and willingness-to-pay research.

Yes. BioNixus designs and executes Polish HCP research in compliance with bioethics committee (komisja bioetyczna) approval requirements where applicable and GDPR/RODO data privacy standards. For studies requiring ethics review, BioNixus supports protocol development and ethics documentation. All Polish respondent recruitment is consent-based with documented data handling procedures, conducted in Polish with English-language reporting for international sponsors.

Scope drives cost: a focused Polish physician quantitative survey often starts in the low-to-mid five figures EUR; full mixed-method access programs with payer mapping and KOL depth interviews are higher. BioNixus scopes programs to one decision per phase so sponsors avoid unfocused fieldwork spend. The Polish market requires verified HCP recruitment, ethics-aligned protocols, and GDPR/RODO-compliant data handling — which reflects in project pricing.

BioNixus recruits from major Polish academic medical centres including the Medical University of Warsaw, Jagiellonian University Medical College (Kraków), Maria Sklodowska-Curie National Research Institute of Oncology, Poznań University of Medical Sciences, and the Medical University of Łódź, as well as regional hospital and community practice networks across Poland. For specialty areas such as oncology or rare disease, we extend recruitment to national oncology and rare disease specialty networks.

Yes. Polish modules can run standalone or with comparable cells in the USA, UK, Germany, France, Brazil, Saudi Arabia, or UAE using consistent instruments — enabling global portfolio committees to benchmark Polish market dynamics against international markets with one research partner.